Hepatitis C is a liver disease caused by the hepatitis C virus: this virus can cause both acute and chronic hepatitis infection, which varies in severity from mild illness, lasting several weeks, to a serious lifelong disease.
Hepcinat 12 Weeks
BRAND : HEPCINAT PRICE : 725$ STRENGTH :400MG ACTIVE INGERIDENTS: HEPCINAT-SOFOSBUVIR-400MG COMPANY NAME : NATCO TABLETS COUNT : 28 TABLETS read more
HEPCINAT (SOFOSBUVIR 400MG)
Hepcinat (Sofosbuvir 400mg) is a prescription medicine used with other antiviral medicines to treat adults with chronic hepatitis C (Hep C) with or without cirrhosis (compensated). Hepcinat recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir to cure genotype 1 to 6 infections. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved. Hepcinat is safe and effective in patient who have had a liver transplant.
Hepcinat (Sofosbuvir 400mg) is activated in the liver to the triphosphate GS-461203 by hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1 (HINT1), and subsequent repeated phosphorylation. Dephosphorylation creates the inactive metabolite GS-331077. The half life of Hepcinat is 0.4 hours, and the half life of GS-331007 is 27 hours.
Following a single 400 mg oral dose of Hepcinat, 80% is excreted in urine, 14% in feces, and 2.5% in expired air recovery. However, of the urine recovery 78% was the metabolite (GS-331007) and 3.5% was Hepcinat.
Hepcinat (Sofosbuvir 400mg) has a number of ideal properties, once daily dosing, no meal restrictions, few adverse effects, minimal drug-drug interactions, high genetic barrier to resistance, good safety and efficacy in patients with advanced liver disease, and excellent sustained virologic response rates in patients with unfavorable baseline characteristics.
Hepcinat (Sofosbuvir 400mg) (in combination with ledipasvir, daclatasvir or simeprevir) should not be used with amiodarone due to the risk of abnormally slow heartbeats.
Hepcinat (Sofosbuvir 400mg) is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut. Therefore, inducers of intestinal P-glycoprotein, such as rifampicin and St. John's wort, could reduce the absorption of Hepcinat.
In addition, coadministration of Hepcinat with anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine), antimycobacterials (rifampin, rifabutin, rifapentine), and the HIV protease inhibitor tipranavir and ritonavir is expected to decrease Hepcinat concentration. Thus, coadministration is not recommended.
The interaction between Hepcinat and a number of other drugs, such as ciclosporin, darunavir/ritonavir, efavirenz, emtricitabine, methadone, raltegravir, rilpivirine, tacrolimus, or tenofovir disoproxil, were evaluated in clinical trials and no dose adjustment is needed for any of these drugs.